Programming superior cells: translational progress at the Altius Institute for Biomedical Sciences and Umoja Biopharma

Cell & Gene Therapy Insights 2020; 6(1), 33-39


Published: 5 February 2020
Shon Green

Shon Green is trained at UC Berkeley and UCSF where she developed and employed preclinical models of cancer to study tumor development and potential therapeutic approaches. She utilized these expertise to drive the preclinical development of T cell-based immunotherapies targeting both solid and liquid tumors at Eureka Therapeutics Inc. (Emeryville, CA, USA), where she successfully guided two novel programs through preclinical proof-of-concept and safety studies to support investigational new drug applications and clinical testing. Since July 2018, she has been directing the development and clinical translation of novel genetic and epigenetic editing tools to enhance cellular therapies for cancer at Altius Institute for Biomedical Sciences (Seattle, WA, USA). She currently also serves as the head of Translational R&D at Umoja Biopharma, a new startup in Seattle, where she is leading the preclinical strategy to obtain proof-of-concept for potentially disruptive new approaches to cancer immunotherapy.